The Cancer Letter
@TheCancerLetter
Followers
27K
Following
383
Media
6K
Statuses
12K
The leading independent source for information on the issues that shape #oncology since 1973. Historical initiative: @cancerhistproj
Washington, D.C.
Joined March 2009
New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate. https://t.co/CPoDFwR5s8
cancerletter.com
New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to...
0
0
0
FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma https://t.co/xD7VifnPeE
cancerletter.com
FDA and OS Therapies held a Type C meeting regarding the phase IIb human clinical trial of OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. To...
0
0
0
Proton vs. traditional radiation therapy significantly improves survival in head and neck cancers, @MDAndersonNews-led study finds https://t.co/LhZTZUM11g
0
0
1
“Cancer research is apolitical,” said Joann Sweasy, director of @BuffettCancer and president of @AACI_Cancer. https://t.co/mKO9QRpn9J
cancerletter.com
As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own. To access this...
0
1
1
.@NorthwellHealth, @TheSTARTCenter unveil $5.7M early-phase clinical trial center https://t.co/pmZogEs1uS
cancerletter.com
Deborah Schrag, a gastrointestinal medical oncologist and George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center, was elected 2027-28 president of the American...
0
0
0
Harvey Risch appointed chair of President’s Cancer Panel https://t.co/iUPzWkE1Kt
cancerletter.com
Harvey A. Risch, professor emeritus and senior research scientist at Yale School of Public Health, was named chair of the President’s Cancer Panel. To access this subscriber-only content please log...
0
0
0
2025 has, indisputably, been a year of change in oncology as the field grapples with shifting policy directions, RIFs, and uncertainty stemming from the Trump administration’s MAHA mission. https://t.co/grJm0A3aK4
cancerletter.com
2025 has, indisputably, been a year of change in oncology as the field grapples with shifting policy directions, RIFs, and uncertainty stemming from the Trump administration’s MAHA mission. Since...
0
0
2
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer https://t.co/yxqiwG9uuG
cancerletter.com
FDA has approved rucaparib (Rubraca) for adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer previously treated with an...
0
0
0
Should I have a drink tonight? In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in https://t.co/CPoDFwR5s8
cancerletter.com
New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to...
0
1
0
Mitochondrial-targeting drug attacks cancer cells from within - guest editorial by @muschollings' Hayley Kamin https://t.co/i9ZTCA01ZN
cancerletter.com
Researchers at MUSC Hollings Cancer Center have identified a promising new weapon in the fight against head and neck cancers. The preclinical drug attacks cancer cells from within by damaging their...
0
0
1
Guest editorial by @hopkinskimmel's Richard J. Jones: With streamlined, “sitevisitless” CCSG review in place, cancer centers remained stable in 2025 https://t.co/UFUqRcWIfM
0
1
0
Angelo de Claro named acting director of FDA Oncology Center of Excellence https://t.co/OOJYd8pgDi
cancerletter.com
Angelo de Claro was named acting director of the FDA Oncology Center of Excellence, following Richard Pazdur’s departure from that position—and the agency (The Cancer Letter, Dec. 5, 2025). To access...
0
0
0
The Directors: Joann Sweasy (@BuffettCancer) and Robert Winn (@VCUMassey) reflect on lessons learned during a tough year Former and current @AACI_Cancer presidents agree: strategic communication is key to safeguarding the future of cancer research https://t.co/mKO9QRpn9J
cancerletter.com
As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own. To access this...
0
0
1
The Cancer Letter’s most-read stories of 2025: As MAHA-led policies took hold, oncology navigated through uncertainty and turmoil https://t.co/grJm0A3aK4
cancerletter.com
2025 has, indisputably, been a year of change in oncology as the field grapples with shifting policy directions, RIFs, and uncertainty stemming from the Trump administration’s MAHA mission. Since...
0
0
1
Eflornithine + lomustine extend OS for patients with recurrent IDH mutant, grade 3 astrocytoma, phase III data show https://t.co/Vao1brej1Y
cancerletter.com
Phase III STELLAR clinical study results have demonstrated that the combination of eflornithine and lomustine achieved clinically meaningful improvements in overall survival and progression-free...
0
0
0
Public health advocates and lawmakers expressed outrage over the withdrawal, with one congressional critic calling it “reckless and dangerous.” https://t.co/Xa6mqRCmbE
cancerletter.com
FDA has withdrawn a proposed rule that called for standardized testing for detecting and identifying asbestos in talc-containing cosmetic products. To access this subscriber-only content please log...
0
0
0
Off-the-shelf immunotherapy produces deep and durable responses in extramedulary MM, @MayoClinic researchers find https://t.co/DcVZ96AVrJ
0
0
0
Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it? https://t.co/GQ96BgANhF
cancerletter.com
Last month, FDA withdrew a proposed rule for standardized asbestos testing in talc-based cosmetics. The proposed rule, introduced in Nov. 2024 and withdrawn Nov. 2025, was mandated by the Moderniza...
0
0
0